Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

OrbiMed Closes Pan-Asia Healthcare Fund with $325 Million

publication date: Sep 10, 2014
OrbiMed Advisors closed its pan-Asia healthcare fund, OrbiMed Asia Partners II L.P., with $325 million in capital. That is much higher than the $188 million raised for the company's first Asia fund and slightly above the $300 million target. OrbiMed plans to make between 15 and 20 investments from the fund with a $40 million cap on any one transaction. However, if appropriate, OrbiMed's global fund could contribute and bring the total up to $100 million. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020